Sanjay Bhandari1, Thangam Venkatesan2. 1. Division of General Internal Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI, 53226, USA. sbhandari@mcw.edu. 2. Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract
BACKGROUND: Data on cyclic vomiting syndrome (CVS) are limited to studies from tertiary care centers. There is a paucity of information about CVS on a national scale. AIM: To study the clinical characteristics, comorbidities, and hospital outcomes in patients hospitalized with CVS using a nationwide database. METHODS: We identified all hospitalizations associated with a primary diagnosis of CVS in 2010 and 2011 using the Nationwide Inpatient Sample with an age category of 18-55 years. A 1:2 random sample of non-CVS hospitalizations with the same age category was obtained, and comparisons between groups were made. Multivariate logistic regression analysis was used to determine comorbidities independently associated with CVS. RESULTS: Our study included 20,952 CVS and 44,262 non-CVS patients. CVS patients tended to be younger, male, and white compared to non-CVS patients. On multivariate analysis, CVS was significantly associated with comorbidities including dysautonomia, migraine, anxiety, marijuana use, irritable bowel syndrome, gastroparesis, gastroesophageal reflux disease, asthma, cigarette smoking, and hypertension. CVS patients underwent esophagogastroduodenoscopy, colonoscopy, and gastric emptying tests more frequently. They had more favorable hospital outcomes like more routine discharges (discharge to home/self-care), lower mortality, and shorter length of stay but tended to leave against medical advice more frequently. CVS patients incurred total hospital charges of about $400 million over the 2 years. CONCLUSIONS: Our study showed that CVS is associated with several comorbidities and incurred substantial health care costs despite benign outcomes. Efforts to optimize therapy of CVS, manage comorbid conditions and reduce healthcare utilization are warranted.
BACKGROUND: Data on cyclic vomiting syndrome (CVS) are limited to studies from tertiary care centers. There is a paucity of information about CVS on a national scale. AIM: To study the clinical characteristics, comorbidities, and hospital outcomes in patients hospitalized with CVS using a nationwide database. METHODS: We identified all hospitalizations associated with a primary diagnosis of CVS in 2010 and 2011 using the Nationwide Inpatient Sample with an age category of 18-55 years. A 1:2 random sample of non-CVS hospitalizations with the same age category was obtained, and comparisons between groups were made. Multivariate logistic regression analysis was used to determine comorbidities independently associated with CVS. RESULTS: Our study included 20,952 CVS and 44,262 non-CVS patients. CVS patients tended to be younger, male, and white compared to non-CVS patients. On multivariate analysis, CVS was significantly associated with comorbidities including dysautonomia, migraine, anxiety, marijuana use, irritable bowel syndrome, gastroparesis, gastroesophageal reflux disease, asthma, cigarette smoking, and hypertension. CVS patients underwent esophagogastroduodenoscopy, colonoscopy, and gastric emptying tests more frequently. They had more favorable hospital outcomes like more routine discharges (discharge to home/self-care), lower mortality, and shorter length of stay but tended to leave against medical advice more frequently. CVS patients incurred total hospital charges of about $400 million over the 2 years. CONCLUSIONS: Our study showed that CVS is associated with several comorbidities and incurred substantial health care costs despite benign outcomes. Efforts to optimize therapy of CVS, manage comorbid conditions and reduce healthcare utilization are warranted.
Authors: T Venkatesan; T Prieto; A Barboi; B Li; A Schroeder; W Hogan; A Ananthakrishnan; S Jaradeh Journal: Neurogastroenterol Motil Date: 2010-12 Impact factor: 3.598
Authors: B Wallaert; P Desreumaux; M C Copin; I Tillie; A Benard; J F Colombel; B Gosselin; A B Tonnel; A Janin Journal: J Exp Med Date: 1995-12-01 Impact factor: 14.307
Authors: T L Abell; K A Adams; R G Boles; A Bousvaros; S K F Chong; D R Fleisher; W L Hasler; P E Hyman; R M Issenman; B U K Li; S L Linder; E A Mayer; R W McCallum; K Olden; H P Parkman; C D Rudolph; Y Taché; S Tarbell; N Vakil Journal: Neurogastroenterol Motil Date: 2008-04 Impact factor: 3.598
Authors: William L Hasler; David J Levinthal; Sally E Tarbell; Kathleen A Adams; B U K Li; Robert M Issenman; Irene Sarosiek; Safwan S Jaradeh; Ravi N Sharaf; Shahnaz Sultan; Thangam Venkatesan Journal: Neurogastroenterol Motil Date: 2019-06 Impact factor: 3.598